Fibrous dysplasia is described as a genetic, non-inheritable disorder caused by osteoblastic differentiation defects. No specific gene is listed in this packet and no inheritance pattern is established. The condition does not run in families.

Specific diagnostic methods are not detailed in this packet. The condition is identified through its characteristic skeletal manifestations, including fibrous replacement of bone with associated structural and morphological changes.

No FDA-approved treatments are listed in this packet for fibrous dysplasia. Several clinical trials are currently active or in recruitment for this condition and related skeletal disorders.

Prognosis data is not available in this packet.

Several clinical trials are currently active or in development for fibrous dysplasia. Ongoing research includes epidemiological and multimodal data collection studies, biomechanical assessment of fracture risk in rare bone disorders including the fibrous dysplasia and McCune-Albright syndrome spectrum, and characterization of pain across this spectrum. Studies are primarily sponsored by academic medical centers and orthopedic institutions.